Cancer Chemotherapy and Pharmacology - Emerging Leaders

René J. Boosman PharmD, completed his Ph.D. on precision dosing strategies for non-small lung cancer in 2022 at the Netherlands Cancer Institute (affiliated with the University of Utrecht, Utrecht, the Netherlands). During his Ph.D. he participated in a training program to become a clinical pharmacologist. Currently, he is a resident in the OLVG hospital in Amsterdam to become a hospital pharmacist.

Corresponding author of "Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial (this opens in a new tab)".

Steffie Groenland graduated cum laude as a medical doctor at the VU Medical Center in Amsterdam in 2016. She completed her PhD at the Netherlands Cancer Institute on optimizing exposure of oral targeted therapies in oncology by precision dosing in 2021. During her PhD, she also trained as a clinical pharmacologist. Currently, she is working as an internal medicine resident. In the future, she aims to specialize in oncology and/or hematology, and combine her clinical work with research in the field of clinical pharmacology.

Corresponding author of "Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients (this opens in a new tab)".

Sean Rudd completed his PhD in Biochemistry in 2013 at the Genome Damage and Stability Centre (University of Sussex, UK), with a thesis centred upon understanding how eukaryotic cells tolerate DNA damage during genome duplication. For his postdoctoral research, conducted at Karolinska Institutet (Sweden), he investigated how damaged DNA precursors influence genome stability in cancer cells and whether this can be exploited therapeutically. In 2019, he established his independent research at SciLifeLab and Karolinska Institutet which seeks to better understand the metabolism and molecular mode-of-action of commonly used chemotherapies and use this knowledge to design strategies to refine their use.

Corresponding author of "Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities (this opens in a new tab)".